Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 13,105
  • Shares Outstanding, K 74,883
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,650 K
  • 60-Month Beta -0.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GTBP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.53
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1470 +22.52%
on 09/09/20
0.2200 -18.14%
on 09/28/20
-0.0089 (-4.71%)
since 09/01/20
3-Month
0.1201 +49.96%
on 07/08/20
0.2500 -27.96%
on 07/21/20
+0.0351 (+24.21%)
since 07/01/20
52-Week
0.0650 +177.08%
on 12/18/19
0.2690 -33.05%
on 03/10/20
+0.0202 (+12.63%)
since 10/01/19

Most Recent Stories

More News
GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update

BEVERLY HILLS, CA / ACCESSWIRE / September 22, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager...

GTBP : 0.1850 (+5.71%)
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection

LOS ANGELES, CA / ACCESSWIRE / August 20, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) (the "Company" or "GT Biopharma") a company focused on developing innovative therapeutic treatments based on its...

GTBP : 0.1850 (+5.71%)
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial

BEVERLY HILLS, CA / ACCESSWIRE / August 4, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager...

GTBP : 0.1850 (+5.71%)
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

FIRST PATIENT ACHIEVED STABLE DISEASE WITH NO ADVERSE SIDE EFFECTS

GTBP : 0.1850 (+5.71%)
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy

Patient Achieved Stable Disease

GTBP : 0.1850 (+5.71%)
UPDATE: GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia

Patient Achieves Stable Disease

GTBP : 0.1850 (+5.71%)
GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia

BEVERLY HILLS, CA / ACCESSWIRE / March 19, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a biotherapeutics company focused on developing innovative therapeutic treatments in oncology and infectious diseases...

GTBP : 0.1850 (+5.71%)
GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection

BEVERLY HILLS, CA / ACCESSWIRE / March 10, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™)...

GTBP : 0.1850 (+5.71%)
GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

TAMPA, FL / ACCESSWIRE / February 26, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™)...

GTBP : 0.1850 (+5.71%)
GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills

TAMPA, Florida , Oct. 22, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager...

GTBP : 0.1850 (+5.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

2nd Resistance Point 0.2215
1st Resistance Point 0.1983
Last Price 0.1850
1st Support Level 0.1634
2nd Support Level 0.1517

See More

52-Week High 0.2690
Fibonacci 61.8% 0.1911
Last Price 0.1850
Fibonacci 50% 0.1670
Fibonacci 38.2% 0.1429
52-Week Low 0.0650

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar